哌拉西林/他唑巴坦与头孢哌酮/舒巴坦治疗细菌性感染疗效的Meta分析

Meta-analysis of piperacillin/tazobactam and cefoperazone/sulbactam for bacterial infection

目的系统评价头孢哌酮/舒巴坦与哌拉西林/他唑巴坦治疗细菌性感染的有效性和安全性。方法检索4个中文数据库及外文期刊数据库,共筛查到8篇比较头孢哌酮-舒巴坦与哌拉西林-他唑巴坦治疗细菌性感染疗效的随机临床试验研究,采用Rev Man 5.3和Stata 12.1软件进行Meta分析。结果采用固定效应模式进行数据统计,头孢哌酮/舒巴坦与哌拉西林/他唑巴坦治疗细菌性感染的治愈率计算OR值（95%CI）为0.91（0.62-1.33）,有效率计算OR值（95%CI）为1.00（0.60-1.67）,不良反应率计算OR值（95%CI）为0.80（0.35-1.85）,清除率计算OR值（95%CI）为1.85（1.05-3.26）,合并效应量检验P值分别为0.62、0.99、0.61和0.03;Egger线性回归法得出P=0.90,95%CI：-0.59-0.66。结论哌拉西林/他唑巴坦治疗细菌性感染的有效性和安全性并不逊于头孢哌酮/舒巴坦。

Objective To evaluate the efficiency and safety of piperacillin/tazobactam and cefoperazone/sulbactam. Methods Eight randomized control trials comparing the effect of treatment between piperacillin/tazobactam and cefoperazone/sulbactam were retrieved through the four Chinese database and foreign language periodicals database. The data of these articles were processed with Meta analysis by Rev Man 5.3 and Stata 12.1 softwares. Results The data were statistically analyzed by the fixed effects model, the pooled odds ratio [OR（95%CI）] of the cure rates, eficacy rates, adverse reaction rates and adverse reactions rates of piperacillin/tazobactam and cefoperazone/sulbactam for bacterialinfection were 0.91（0.62-1.33）, 1.00（0.60-1.67）, 1.00（0.60-1.67） and 1.85（1.05-3.26）, respectively, the combined effect of P were 0.62, 0.99, 0.61 and 0.03. The results showed that P = 0.90, 95%CI：-0.59-0.66 by the Egger linear regression method. Conclusion Piperacillin/tazobactam and cefoperazone/sulbactam had the same safety and efficiency.